Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060384 · ClinicalTrials.gov registry record · Phase 1
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01060384 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 46 participants.
The verdict
NCT01060384, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this trial is to investigate the efficacy (how well the drug works) of ofatumumab and lenalidomide in patients with lymphoma and to investigate if any possible unwanted side effects may occur. The purpose of the Phase I portion of this trial will be to determine the maximum dose of these medications that can be given with minimal side effects.
Interventions
- DRUG Lenalidomide
- DRUG ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2010-03-29 |
| Est. Completion | 2018-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01060384
The ClinicalTrials.gov registry entry for NCT01060384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT01060384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01060384 about?
NCT01060384 is a clinical study titled "Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma". The purpose of this trial is to investigate the efficacy (how well the drug works) of ofatumumab and lenalidomide in patients with lymphoma and to investigate if any possible unwanted side effects may occur. The purpose of the Phase I portion of this trial will be to determine the maximum dose of th...
What is the current status of trial NCT01060384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2010-03-29. Estimated completion is 2018-01-01.
What interventions are being tested in trial NCT01060384?
The interventions under investigation include: Lenalidomide (DRUG), ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01060384?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.